Dyskinesia - Pipeline Review, H2 2018

Dyskinesia - Pipeline Review, H2 2018


  • Products Id :- GMDHC10766IDB
  • |
  • Pages: 182
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Dyskinesia-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia-Pipeline Review, H2 2018, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyskinesia-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 16, 4, 17, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 5

Dyskinesia-Overview 6

Dyskinesia-Therapeutics Development 7

Dyskinesia-Therapeutics Assessment 16

Dyskinesia-Companies Involved in Therapeutics Development 24

Dyskinesia-Drug Profiles 36

Dyskinesia-Dormant Projects 159

Dyskinesia-Discontinued Products 162

Dyskinesia-Product Development Milestones 163

Appendix 175

List of Figures

Number of Products under Development for Dyskinesia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development for Dyskinesia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Dyskinesia-Pipeline by Addex Therapeutics Ltd, H2 2018

Dyskinesia-Pipeline by Advicenne SA, H2 2018

Dyskinesia-Pipeline by Amarantus Bioscience Holdings Inc, H2 2018

Dyskinesia-Pipeline by Avanir Pharmaceuticals Inc, H2 2018

Dyskinesia-Pipeline by Cadent Therapeutics, H2 2018

Dyskinesia-Pipeline by Cavion LLC, H2 2018

Dyskinesia-Pipeline by Cerevance Inc, H2 2018

Dyskinesia-Pipeline by Clevexel Pharma SAS, H2 2018

Dyskinesia-Pipeline by DanPET AB, H2 2018

Dyskinesia-Pipeline by EpiVax Inc, H2 2018

Dyskinesia-Pipeline by H. Lundbeck AS, H2 2018

Dyskinesia-Pipeline by Heptares Therapeutics Ltd, H2 2018

Dyskinesia-Pipeline by India Globalization Capital Inc, H2 2018

Dyskinesia-Pipeline by Ipsen SA, H2 2018

Dyskinesia-Pipeline by IRLAB Therapeutics AB, H2 2018

Dyskinesia-Pipeline by Medy-Tox Inc, H2 2018

Dyskinesia-Pipeline by Merz Pharma GmbH & Co KgaA, H2 2018

Dyskinesia-Pipeline by Mylan NV, H2 2018

Dyskinesia-Pipeline by Neurim Pharmaceuticals Ltd, H2 2018

Dyskinesia-Pipeline by Neurocrine Biosciences Inc, H2 2018

Dyskinesia-Pipeline by Neurolixis Inc, H2 2018

Dyskinesia-Pipeline by Newron Pharmaceuticals SpA, H2 2018

Dyskinesia-Pipeline by Phenomenome Discoveries Inc, H2 2018

Dyskinesia-Pipeline by Revance Therapeutics Inc, H2 2018

Dyskinesia-Pipeline by Sage Therapeutics Inc, H2 2018

Dyskinesia-Pipeline by SOM Biotech SL, H2 2018

Dyskinesia-Pipeline by Ultragenyx Pharmaceutical Inc, H2 2018

Dyskinesia-Dormant Projects, H2 2018

Dyskinesia-Dormant Projects, H2 2018 (Contd..1), H2 2018

Dyskinesia-Dormant Projects, H2 2018 (Contd..2), H2 2018

Dyskinesia-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Addex Therapeutics Ltd

Advicenne SA

Amarantus Bioscience Holdings Inc

Avanir Pharmaceuticals Inc

Cadent Therapeutics

Cavion LLC

Cerevance Inc

Clevexel Pharma SAS

DanPET AB

EpiVax Inc

H. Lundbeck AS

Heptares Therapeutics Ltd

India Globalization Capital Inc

Ipsen SA

IRLAB Therapeutics AB

Medy-Tox Inc

Merz Pharma GmbH & Co KgaA

Mylan NV

Neurim Pharmaceuticals Ltd

Neurocrine Biosciences Inc

Neurolixis Inc

Newron Pharmaceuticals SpA

Phenomenome Discoveries Inc

Revance Therapeutics Inc

Sage Therapeutics Inc

SOM Biotech SL

Ultragenyx Pharmaceutical Inc

Dyskinesia Therapeutic Products under Development, Key Players in Dyskinesia Therapeutics, Dyskinesia Pipeline Overview, Dyskinesia Pipeline, Dyskinesia Pipeline Assessment

select a license
Single User License
USD 2000 INR 142720
Site License
USD 4000 INR 285440
Corporate User License
USD 6000 INR 428160

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com